Scailyte

Scailyte is a Basel-based TechBio company building a deep AI foundation model for autoimmune diseases, anchored by a massive single-cell and spatial omics data asset. Its flagship program targets Inflammatory Bowel Disease (IBD), aiming to de-risk drug development, discover novel targets, and create precision diagnostics through advanced patient endotyping. The company operates a partnership-driven business model, offering its platform and insights to pharmaceutical companies to navigate the shift towards high-efficacy precision treatments in immunology.

ScaiVision™: A proprietary AI platform using Supervised Representation Learning and Deep Generative Models trained on vast single-cell and spatial omics data matched with clinical outcomes for patient endotyping and predictive disease modeling.

Scailyte competes with other AI-driven drug discovery platforms (e.g., Recursion, Exscientia, insitro) and biotechs focused on single-cell analytics. Its key differentiation is the deep, autoimmune-focused foundation model and exclusive access to longitudinal cohort data like the Swiss IBD Cohort.